Replies to post #462356 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

My opinion remains unchanged in that only an actual CHMP validated MAA filing that subsequently survives the EMA process clock-stop 1 would significantly improve the $AVXL price. Surviving clock-stop 1 is the hardest per the EMA published stats.

We can always hope that the July 28th AAIC presentation moves the needle. I also still have a sense that the AAIC presentation may mean no peer review published. If that turns out to be the case and the market waited in vain for the peer review 'catalyst', then only the MAA filing and its progress can help the price of $AVXL. Starting new trials is great, but will represent more cost for several years without revenue insight.

Let's see, I may well be too sceptical.